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Genetics
Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy
Pathogenic Desmosome Mutations in Index-Patients Predict Outcome of
Family Screening: Dutch Arrhythmogenic Right Ventricular
Dysplasia/Cardiomyopathy Genotype-Phenotype Follow-Up Study
Moniek G.P.J. Cox, MD, PhD*; Paul A. van der Zwaag, MD*; Christian van der Werf, MD*;
Jasper J. van der Smagt, MD; Maartje Noorman, MSc; Zahir A. Bhuiyan, MD, PhD;
Ans C.P. Wiesfeld, MD, PhD; Paul G.A. Volders, MD, PhD; Irene M. van Langen, MD, PhD;
Douwe E. Atsma, MD, PhD; Dennis Dooijes, PhD; Arthur van den Wijngaard, PhD;
Arjan C. Houweling, MD, PhD; Jan D.H. Jongbloed, PhD; Luc Jordaens, MD, PhD;
Maarten J. Cramer, MD, PhD; Pieter A. Doevendans, MD, PhD; Jacques M.T. de Bakker, PhD;
Arthur A.M. Wilde, MD, PhD; J. Peter van Tintelen, MD, PhD; Richard N.W. Hauer, MD, PhD
Background—Arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C) is an autosomal dominant
inherited disease with incomplete penetrance and variable expression. Causative mutations in genes encoding 5
desmosomal proteins are found in 50% of ARVD/C index patients. Previous genotype-phenotype relation studies
involved mainly overt ARVD/C index patients, so follow-up data on relatives are scarce.
Methods and Results—One hundred forty-nine ARVD/C index patients (111 male patients; age, 4913 years)
according to 2010 Task Force criteria and 302 relatives from 93 families (282 asymptomatic; 135 male patients;
age, 4413 years) were clinically and genetically characterized. DNA analysis comprised sequencing of
plakophilin-2 (PKP2), desmocollin-2, desmoglein-2, desmoplakin, and plakoglobin and multiplex ligation-
dependent probe amplification to identify large deletions in PKP2. Pathogenic mutations were found in 87 index
patients (58%), mainly truncating PKP2 mutations, including 3 cases with multiple mutations. Multiplex
ligation-dependent probe amplification revealed 3 PKP2 exon deletions. ARVD/C was diagnosed in 31% of
initially asymptomatic mutation-carrying relatives and 5% of initially asymptomatic relatives of index patients
without mutation. Prolonged terminal activation duration was observed more than negative T waves in V1 to V3,
especially in mutation-carrying relatives 20 years of age. In 45% of screened families, 1 affected relatives were
identified (90% with mutations).
Conclusions—Pathogenic desmosomal gene mutations, mainly truncating PKP2 mutations, underlie ARVD/C in the
majority (58%) of Dutch index patients and even 90% of familial cases. Additional multiplex ligation-dependent probe
amplification analysis contributed to discovering pathogenic mutations underlying ARVD/C. Discovering pathogenic
mutations in index patients enables those relatives who have a 6-fold increased risk of ARVD/C diagnosis to be
identified. Prolonged terminal activation duration seems to be a first sign of ARVD/C in young asymptomatic
relatives. (Circulation. 2011;123:2690-2700.)
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Arrhythmogenic right ventricular dysplasia/cardiomyopa-thy (ARVD/C) is histopathologically characterized by
progressive fibrofatty replacement of myocardium, primarily
of the right ventricle (RV).1–3 Although familial occurrence
was recognized in the first report, only in the last decade has
the genetic substrate been identified in genes encoding
desmosomal proteins.1,4–9 Desmosomes are protein com-
plexes in the intercalated disk, among others responsible for
mechanical coupling of cardiac myocytes. Their impairment
leads to both mechanical and electric uncoupling of cardio-
myocytes, followed by cell death with fibrofatty replace-
ment.10–13 Both uncoupling and altered architecture result in
activation delay, which is the pivotal mechanism for reentry
and thus ventricular tachycardia (VT).14–16
Editorial see p 2661
Clinical Perspective on p 2700
Arrhythmogenic right ventricular dysplasia/cardiomyopa-
thy usually shows an autosomal dominant inheritance pattern,
with incomplete penetrance and highly variable clinical
expression.1,17–20 Classically, index patients present between
the second and fourth decades of life with VT originating
from the RV. However, sudden death can occur as early as
adolescence, whereas mutation carriers may also remain
without any signs and symptoms into old age. It has been
hypothesized that genetic modifiers could be responsible for
this phenotypic variability.4,5,7,21–24
One of the primary clinical challenges in ARVD/C is
timely diagnosis of the concealed phase, when individuals are
at risk for arrhythmias despite the absence of symptoms. Yet,
previous studies on genotype-phenotype correlations in-
volved mainly overt ARVD/C index patients.17–24 Follow-up
data on their relatives are scarce. Hence, the proportion of
relatives who develop signs of ARVD/C and/or (fatal) ar-
rhythmias is unknown.
Analyzing multiple genes related to ARVD/C in all index
patients is essential for both accurate diagnosis and appropri-
ate family counseling and screening. More insight into the
natural variability of the disease expression and phenotypic
consequences of genetic findings of ARVD/C is required. We
therefore sequenced all 5 desmosomal genes in 149 Dutch
ARVD/C index patients. The 302 family members were
screened for the pathogenic mutations identified in their
respective index patients. All individuals were followed up
for genotype-phenotype correlations to determine disease
penetrance and expression, including arrhythmias and sudden
death.
Methods
Patient Population
In total, 169 unrelated white Dutch index patients with ARVD/C
diagnosed according to the recently modified diagnostic Task Force
criteria (2010 TFC) or at autopsy were included.25 An index patient
was the first member of the family diagnosed with ARVD/C in
whom DNA analysis was started. The diagnostic process included
detailed clinical and family histories, a physical examination, a
12-lead ECG, exercise testing, chest x-ray, and 2-dimensional
transthoracic echocardiography. If no VT had been recorded, 24-
hour Holter monitoring was performed. Additional magnetic reso-
nance imaging and/or left ventricular and RV cine-angiography was
performed in 118 patients (70%), and electrophysiological studies
were done in 105 patients (62%). See Table I in the online-only Data
Supplement for details on follow-up frequencies.
We also included 302 relatives of 93 index patients who under-
went cardiologic evaluation comprising at least a detailed history,
physical examination, 12-lead ECG, and 2-dimensional echocardi-
ography. If performed, outcomes of exercise tests (in 59%), 24-hour
Holter monitoring (in 66%), signal-averaged ECG (in 25%), and
electrophysiological studies (12%), as well as additional imaging by
magnetic resonance imaging and/or RV cine angiography (42%),
were included.
All 169 families received genetic counseling and consented to
both clinical evaluation according to 2010 TFC and genetic screen-
ing of ARVD/C-related genes.25 Quantitative analyses were per-
formed at the 7 participating centers. Scoring was performed in the
core laboratory in Utrecht, the Netherlands, and patients were
included only if there were no signs of any other cardiac disease.
Diagnostic Criteria
Routine 12-lead ECGs were done with a paper speed of 25 mm/s and
low-pass filter at 100 Hz. Depolarization and repolarization abnor-
malities were analyzed only while patients were off drugs. Epsilon
wave was defined as a distinct deflection after the QRS complex had
first returned to the isoelectric line.26 Terminal activation duration
(TAD) was determined as the longest value in V1 to V3, from the
nadir of the S wave to the end of all depolarization deflections, and
considered prolonged when 55 milliseconds.27 Recordings of VT
episodes, both spontaneous and induced by programmed electric
stimulation during electrophysiological studies, were collected. Ven-
tricular tachycardia morphologies were determined only if 12-lead
ECGs were available. Tissue characterizations from biopsies were
not taken into account, because analyses had not been performed as
prescribed in the 2010 TFC.25
DNA Analysis
Genomic DNA was extracted from whole blood or paraffin-
embedded tissues as described previously.23 Sufficient DNA was
available in 149 patients (88%) for direct sequencing of PKP2,
DSG2, DSC2, DSP, and JUP. In addition, multiplex ligation-
dependent probe amplification analysis was performed to identify
large deletions in PKP2 (SALSA multiplex ligation-dependent probe
amplification kit P168 ARVC-PKP2, MRC Holland, Amsterdam, the
Netherlands). Primer sequences and polymerase chain reaction
conditions are available on request.
Nonsense, frameshift, and splice-site mutations affecting positions
2, 1, 1, and 2, as well as PKP2 exon deletions, were all
labeled truncating and considered to be proven pathogenic unless
identified as polymorphisms. To assess the possible pathogenic
nature of missense mutations, we used the in silico predictive
programs Sorting Intolerant From Tolerant (SIFT) and Polymor-
phism Phenotyping (PolyPhen), which use the following criteria:
difference in physicochemical properties of amino acids in respective
substitutions, evolutionary conservation of amino acids across sev-
eral species, presence in an evolutionary conserved region, and
localization in a predicted or proven functionally important do-
main.28,29 Missense mutations were considered to be most likely
pathogenic when both programs predicted the genetic variants to
affect protein function by a tolerance index score of 0.05 (SIFT)
and the classification “probably damaging” (PolyPhen).28,29 Variants
suspected of pathogenicity also had to be absent in 200 ethnically
matched (ie, white Dutch) control subjects after direct sequencing.
When available, data on segregation were taken into account. Family
members were screened only for the pathogenic mutation found in
their respective index patient. For genotype-phenotype analyses,
proven pathogenic and most likely pathogenic variants were together
labeled pathogenic, and comparisons of truncating and missense
mutations were made. All variants present in the general population
with a frequency of 1% were considered to be sequence poly-
morphisms. Sequence variants that did not fulfill our criteria for
pathogenicity and were not polymorphisms were labeled unclassified
variants (UVs).
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In this article, “patients with mutations” and “mutation carriers”
refer to patients carrying pathogenic mutations as identified in this
study.
Statistical Analysis
Continuous variables were compared by use of the Student t test.
Categorical variables were analyzed by use of contingency tables and
the Pearson 2 method. If the expected value was 5, the Fisher
exact test was used instead. To compensate for possible correlation
of characteristics of relatives within families, mixed models with
hierarchical structure of members within families were applied.
When it was impossible to fit the data in these models owing to lack
of variation within families, Pearson 2 tests were applied instead on
a family level (ie, on the presence/absence of characteristics within
separate families). Descriptive statistics are reported as meanSD
and estimates as estimated valueSE. Values of P0.05 were
considered statistically significant. PASW statistics 17.0 software
(SPSS, Chicago, IL) was used for calculations.
Results
Arrhythmogenic Right Ventricular
Dysplasia/Cardiomyopathy Index Patients
Initially, 169 ARVD/C patients fulfilled the 2010 TFC.
Twenty patients were excluded because of incomplete DNA
analyses. PKP2, DSG2, DSC2, DSP, and JUP were all screened
in the remaining 149 patients (111 male patients; mean age at
inclusion, 4913 years). First presentation was at a median age
of 37 years (range, 12 to 77 years), mostly with monomorphic
VT (n122, 82%). These VTs were sustained in 119 cases, and
all but 2 had left bundle-branch block morphology (see Table 1).
Presenting first symptoms were similar between men and
women. Cardioverter-defibrillators were implanted in 95 pa-
tients (64%): in 57 directly after diagnosis and in 38 after 47
years of follow-up. During follow-up, 4 patients died of ventric-
ular fibrillation (3 without implantable cardioverter-
defibrillators, 1 with electrical storm) and 2 died of progressive
heart failure. Three patients were indicated for heart transplan-
tation; 1 received a transplantation.
DNA Analyses
All pathogenic mutations are summarized in Table 2, and
UVs are summarized in Table II in the online-only Data
Supplement. In total, 87 index patients (58%) carried at least
1 mutation (89 total: 70 truncating [68 PKP2] and 19
missense [12 PKP2]).
Table 1. Clinical Characteristics of Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy Index
Patients Related to the Presence or Absence of Pathogenic Mutations
Total
(n147)*
With Mutation
(n87)
No Mutation
(n60)
n % n % n % P
Male 110 75 62 71 48 80 0.284
Age at onset, meanSD, y 3714 3513 4014 0.042
Follow-up, meanSD, y 129 1310 117 0.191
Reason for first evaluation
VT 122 82 72 83 47 78
Aborted sudden death 12 8 8 9 4 7
Prolonged syncope 2 1 1 1 1 2
Sudden death of a relative 2 1 0 0 2 3
Frequent PVCs 5 3 5 6 3 5
Other 4 3 1 1 3 5
TFC
Epsilon wave† 22 18 14 18 8 17 0.153
Late potentials‡ 44 54 22 50 22 59 0.395
Prolonged TAD† 78 62 44 56 34 72 0.734
Negative T waves
V1–V3† 98 78 69 88 29 62 0.001
V1–V2† 8 6 5 6 3 6 1.000
V4–V6† 6 5 2 3 3 6 0.524
Ventricular fibrillation 12 8 8 9 4 7 0.281
LBBB VT with superior axis 67 46 39 45 28 47 0.943
LBBB VT 129 88 77 89 52 87 0.945
PVCs 500/24 h 33 22 20 23 13 22 0.969
Structural major TFC 86 59 55 63 31 52 0.198
Structural minor TFC 25 17 15 17 10 17 0.963
VT indicates ventricular tachycardia; PVC, premature ventricular complex; TFC, Task Force criteria; TAD, terminal activation
duration; and LBBB, left bundle-branch block. P values are the difference between mutation carriers and noncarriers.
*Two patients were diagnosed after autopsy; therefore, no clinical data were available.
†ECGs done while the patients were off drugs were available for 125 index patients: 78 with and 47 without mutation.
‡Late potentials were measured in 81 patients: 69 by signal-averaged ECG and 12 by mapping during electrophysiological studies.
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Single mutations were identified in 84 index patients
(56%): 76 PKP2 (64 truncating), 5 DSG2, 2 DSC2, and 1
DSP. In addition, 3 patients (2%) carried multiple mutations.
Two had a truncating PKP2 mutation and a DSC2 or DSP
missense mutation, and 1 carried a homozygous DSC2
mutation (see Table III in the online-only Data Supplement
for details, including phenotypic characteristics).
We identified 52 UVs in 50 patients (36 different ones;
Table II in the online-only Data Supplement). In 28 patients,
the UV was carried in addition to a pathogenic mutation, and
2 patients carried 2 UVs. Table IV in the online-only Data
Supplement shows the combinations of pathogenic mutations
and UVs per patient. Of the 36 UVs, 29 were missense
variants, 6 were silent variants, and 1 was a frameshift
variant. The DSC2 frameshift variant p.Ala897fs was consid-
ered a UV because it is located at the far end of the gene and
was found in 8 patients and in 3 of 200 controls (P0.06).24
The DSG2 variant p.Val158Gly was predicted to be patho-
Table 2. Pathogenic Mutations
Gene DNA Change Protein Change Type
PolyPhen
(PSIC)* SIFT†
Index
Patients, n
Family
Members
Symptomatic,
n
Yes No
Proven pathogenic
PKP2 Deletion exon 1–4 NA Deletion 1 1 7
Deletion exon 1–14 NA Deletion 1 4
Deletion exon 8 NA Deletion 1
c.148_151delACAG p.Thr50SerfsX61 Frameshift 2 3
c.235CT p.Arg79X Nonsense 9 3 15
c.258TG p.Tyr86X Nonsense 1
c.397CT p.Gln133X Nonsense 9 3 16
c.917_918delCC p.Pro318GlnfsX29 Frameshift 3 1 1
c.1211_1212insT p.Val406SerfsX Frameshift 11 6 15
c.1369_1372delCAAA p.Gln457X Nonsense 2 4
c.1848CA p.Tyr616X Nonsense 4 6
c.2028GA p.Trp676X Nonsense 1 1
c.2034GA p.Trp678X Nonsense 1 2
c.2146-1GC Splice site 7 2
c.2386TC p.Cys796Arg Missense  (3.410) 0.03 11 1 17
c.2421CA p.Tyr807X Nonsense 1
c.24891GA Splice site 6 1 7
c.24894AC† Splice site 4 9
c.2509delA p.Ser837ValfsX94 Frameshift 1
c.2544GA p.Trp848X Nonsense 1 1
DSC2 c.943-1GA Splice site 1 1
DSG2 c.3782TG Splice site 1
DSP c.3337CT p.Arg1113X Nonsense 1 1
Most likely pathogenic
PKP2 c.2062TC p.Ser688Pro Missense  0.04 1 1
DSC2 c.608GA p.Arg203His Missense  (2.295) 0.00‡ 1 2
c.9423AG§ Splice site 1
c.2587GA p.Gly863Arg Missense  (2.492) 0.00‡ 1
DSG2 c.137GA p.Arg46Gln Missense  (2.013) 0.00‡ 2 4
c.614CT p.Pro205Leu Missense  (3.054) 0.00‡ 1
c.874CT p.Arg292Cys Missense  (2.759) 0.00‡ 1 2
DSP c.1982AT p.Asn661Iie Missense  (2.073) 0.01‡ 1
*Polymorphism Phenotyping (PolyPhen) prediction: , probably damaging; , possibly damaging; , benign. PSIC indicates Position-Specific Independent
Counts.
†Sorting Intolerant From Tolerant (SIFT) prediction: Amino acids with scores0.05 are predicted to be deleterious. For previous reports on pathogenicity, see
Reference 31.
‡This substitution may have been predicted to affect function just because the sequences used were not diverse enough. There is low confidence in this prediction.
§The 4 splice-prediction programs used (SpliceSiteFinder, MaxEntScan, NNSPLICE, and GeneSplicer) indicated disruption of the splice donor site of DSC2 exon 7.
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genic by both SIFT and PolyPhen. However, we found this
variant in 2 of 149 patients and 3 of 300 controls (P0.67),
and it has frequently been reported in other control popula-
tions.22,23,30,31 Therefore, we classified it as a UV.
Genotype-Phenotype Correlation
First, we compared the clinical characteristics of index
patients with and without mutations independently of the
number of variants (Table 1). Both groups showed a male
predominance (71% and 80%), and age at the time of
inclusion was similar (5113 and 4913 years).
Ventricular tachycardia and/or ventricular fibrillation was
recorded in 134 of 149 index patients, showing similar
frequencies among those with and without mutations. How-
ever, first arrhythmic events were documented at a signifi-
cantly younger age in mutation carriers compared with
noncarriers (median age, 35 versus 42 years; P0.042;
Figure 1). The 3 patients carrying 2 mutations had their first
VT at 14, 17, and 20 years of age. A comparison of criteria in
mutation carriers and noncarriers demonstrated no significant
differences except that negative T waves in V1 to V3 occurred
more often in mutation carriers (88% versus 62%; P0.001).
None of the criteria could be explained by the type of
mutation (truncating versus missense) except for prolonged
TAD, which was observed more often in patients with
missense mutations (13 of 15 versus 31 of 63).
Patients carrying a single UV did not differ from patients
without mutations on any criterion or on age of first event.
However, fewer patients with a single UV had negative T
waves in V1 to V3 than patients with 1 mutation (P0.043),
but they were similar in every other respect. Likewise,
patients carrying a UV together with a mutation did not differ
from either patients with a single mutation or those with 2
mutations (see Table V in the online-only Data Supplement
for more details).
Family History of Sudden Cardiac Death
Twenty-five index patients reported 30 relatives with sudden
cardiac death (SCD). In 18 families of index patients with
mutations, SCD had occurred in 19 relatives (16 male
subjects). Autopsy was performed in 6 cases and revealed
ARVD/C in all of them. In 7 families of index patients
without mutations, SCD had occurred in 11 relatives (8 male
relatives). No autopsies had been performed. Mean ages at
SCD were similar in families with and without mutations (28
years [range, 15 to 49 years] versus 32 years [range, 21 to 43
years]; P0.108). However, all 7 relatives with SCD at 20
years of age (23%) belonged to families with PKP2 mutations
(6 truncating; Table 3).
Family Members
Both genotypic and phenotypic data were available for
analysis of 302 members from 93 different families (58 with
and 35 without mutations).
Relatives Symptomatic at First Presentation
Twenty relatives from 18 families presented with cardiac symp-
toms before family screening was performed (13 men; mean
age, 42 years [range, 20 to 71 years]). In 10 relatives, mono-
morphic left bundle-branch block VT was the first symptom. In
addition, 4 family members had ventricular fibrillation (1 was
successfully resuscitated), 3 had prolonged syncope, 2 had
palpitations and 1 had atrial fibrillation. Eighteen relatives
fulfilled the 2010 TFC, and 18 carried pathogenic mutations (all
PKP2, 16 truncating; Table 2 and Figure 2).
Family Screening of Asymptomatic Relatives
The remaining 282 asymptomatic relatives (123 male sub-
jects, 44%) were evaluated in the course of family screening.
Mean age at first clinical examination was 3918 years, and
follow-up 44 years, which was similar for male and female
subjects. In 119 members (42%) from 56 families, pathogenic
Figure 1. Ventricular tachycardia/ventricular
fibrillation (VT/VF)–free survival of arrhyth-
mogenic right ventricular dysplasia/cardio-
myopathy (ARVD/C) index patients with vs
without mutations. Patients with a mutation
experience their first arrhythmic event at a
significantly younger age than those without
a mutation. This age is even lower if a
patient carries 2 mutations (see text).
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mutations were identified: in 111 PKP2 (93%; 78% truncat-
ing), 5 DSG2, and 3 DSC2 (Table 2 and Figure 2).
Table 4 shows the results of family screening in the 282
initially asymptomatic family members. Most criteria were
perceived either exclusively or considerably more often in
mutation carriers. Because of the low presence of characteristics
and low variation in families, mixed models could not be applied
to these data. To recognize the possible dependence of relatives
and their phenotypes among families, statistical analyses were
performed at the family level (ie, families were scored positive
Table 3. Relatives <20 Years of Age With Sudden Death or Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy Signs
Age, y Sex PKP2 Mutation in Family† PKP2 Mutation† Autopsy TFC Identified
Sudden cardiac death 15 Male c.235CT No
16 Male c.24891GA‡ No
16 Male c.24891GA‡ No
17 Male c.2386TC Yes (ARVD/C)
17 Male c.397CT No
17 Male c.1211-1212insT Yes (ARVD/C)
18 Female c.2421CA Yes (ARVD/C)
Family screening* 14 Male Deletion exons 1–4 Prolonged TAD
17 Male c.1211-1212insT Prolonged TAD plus 500 PVCs/24 h
18 Male c.24894AC Prolonged TAD
18 Male c.2386TC Prolonged TAD
19 Female c.148_151delACAG Prolonged TAD
15 Male c.1369_1372delCAAA Negative T waves in V1–V2
19 Female c.2386TC Negative T waves in V1–V2
TFC indicates Task Force criteria; ARVD/C, arrhythmogenic right ventricular dysplasia/cardiomyopathy; TAD, terminal activation duration; and PVC, premature
ventricular complex.
*Age after follow-up.
†All mutations in PKP2.
‡From the same family.
Mutations were found in none of the other genes. All mutations were truncating, except missense c.2386TC.
Figure 2. Schematic representation of relatives demonstrating the distribution of arrhythmogenic right ventricular dysplasia/cardiomy-
opathy (ARVD/C) signs and symptoms as well as mutations. Numbers in parentheses indicate the number of different families.
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for separate criteria if present in 1 relative; Table 4). Strik-
ingly, prolonged TAD was observed in more cases than negative
T waves in V1 to V3. This difference varied with age (Figure 3).
Relatives20 years of age had no negative T waves in V1 to V3,
but prolonged TAD was already observed in 5 of 7 young
relatives with signs of ARVD/C (Table 3).
VTs were recorded in 9 initially asymptomatic relatives
(3%) from 8 families. All carried PKP2 mutations (7
truncating; Table 4). Five women (mean age, 51 years
[range, 34 to 70 years]) had hemodynamically well-
tolerated nonsustained left bundle-branch block VT during
their first exercise tests. The other 4 (1 female) had VT
after a mean follow-up of 4 years (2 to 8 years at a mean
age of 43 years [range, 34 to 56 years]. Two left bundle-
branch block VTs were sustained with rates of 220 and 240
bpm, and resulted in syncope.
Table 4. Clinical Characteristics of Asymptomatic Arrhythmogenic Right Ventricular
Dysplasia/Cardiomyopathy Relatives Related to the Presence or Absence of Pathogenic Mutations
Total
(n282)
With Mutation
(n119)
No Mutation
(Index Patient
With
Mutation;
n67)
No Mutation
(Index Patient
No Mutation;
n96)
n % n % n % n % P *
Male 123 44 45 38 32 48 47 49 0.096
Age at first evaluation,
mean, y
3918 3918 4018 3817 0.419
Follow-up, meanSD, y 44 43 43 33 0.131
ARVD/C diagnosis 42 (27) 15 37 (23) 31 0 0 5 (4) 5 0.004
Epsilon wave 4 (4) 1 4 (4) 3 0 0 0 0 0.292
Late potentials† 8 (8) 10 6 (6) 21 0 0 2 (2) 2 0.047
Prolonged TAD 34 (26) 12 26 (21) 22 0 0 8 (5) 8 0.030
Negative T waves
V1–V3 20 (18) 7 19 (17) 16 0 0 1 1 0.002
V1–V2 7 (6) 2 6 (5) 5 0 0 1 1 0.410
V4–V6 3 (2) 1 0 0 0 0 3 (2) 3 0.130
VT with LBBB morphology
With superior axis 2 (2) 1 2 (2) 2 0 0 0 0 0.532
With inferior axis 9 (9) 3 9 (9) 8 0 0 0 0 0.023
500 PVCs/24 h 34 (19) 12 23 (14) 19 0 0 9 (5) 9 0.304
Structural abnormalities
Major 12 (11) 4 10 (9) 8 0 0 2 (2) 2 0.315
Minor 10 (7) 4 10 (7) 8 0 0 0 0 0.045
ARVD/C indicates arrhythmogenic right ventricular dysplasia/cardiomyopathy; TAD, terminal activation duration; VT, ventricular
tachycardia; LBBB, left bundle-branch block; PVC, premature ventricular complex.
*Difference between families of relatives with mutation vs relatives of index patients without mutation. Numbers in parentheses
indicate the numbers of different families.
†Late potentials were measured in 77 patients: 29 with and 48 without mutation.
Figure 3. Presence of prolonged terminal activation duration (TAD) and negative T waves in V1 to V3 per age group in relatives with
mutation vs relatives from index patients without mutation. Prolonged TAD was already present in many young relatives, with similar
frequencies among all age groups (P0.269). On the contrary, negative T waves were present more frequently with increasing age,
almost exclusively in mutation carriers. Numbers in parentheses indicate the numbers of relatives per age group.
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Altogether, 57 family members (20%) from 35 families
showed signs of ARVD/C because they fulfilled 1 criteria
besides those concerning family history. This group com-
prised more women than men (39 versus 18; P0.04), and
their mean age after follow-up was 4716 years. Forty-eight
(84%) carried pathogenic mutations (all PKP2, 41 truncat-
ing), and the remaining 9 belonged to families with no
identified mutation. Fourteen relatives with an unremarkable
first clinical evaluation developed signs of ARVD/C after a
mean follow-up of 4.2 years (range, 1 to 10 years). For family
members up to 50 years of age, a higher age was associated
with an increased prevalence of ARVD/C signs, in contrast to
family members 50 years of age (Figure 4).
Forty-two initially asymptomatic family members from 27
families were diagnosed with ARVD/C: at first evaluation in
34 patients and after a mean follow-up of 5.0 years (range, 2
to 10 years) in 8 patients. This group had a mean age at
diagnosis of 3915 years and comprised 29 females (69%).
Familial Risk of Arrhythmogenic Right Ventricular
Dysplasia/Cardiomyopathy
In initially asymptomatic relatives, ARVD/C was diagnosed
in 5% (5 of 96) when their index patient had no identified
mutation and 20% (37 of 11967) when their index patient
had a mutation; all 37 also carried mutations (Figure 2). Thus,
identifying a mutation in an index patient implies a relative
risk for ARVD/C diagnosis in their asymptomatic relatives of
3.81.6. This risk increases to as much as 6.02.4 for
mutation-carrying relatives compared with relatives of index
patients without a mutation (37 of 119 versus 5 of 96).
When the symptomatic and asymptomatic mutation-
carrying relatives were combined, 54 of 137 (39%) had an
ARVD/C diagnosis compared with 6 of 98 relatives of index
patients without mutations (6%).
Of the 93 families in which 2 members, including the
index patient, were examined, 42 had familial ARVD/C
(45%; 38 with mutations, all PKP2, 33 truncating). Thus,
PKP2 mutations were identified in 90% of familial ARVD/C
cases.
Discussion
Here, we report the results of follow-up of a large number of
ARVD/C families, including comprehensive DNA analysis.
In 87 of 149 ARVD/C index patients (58%), pathogenic
mutations were identified, predominantly truncating PKP2.
ARVD/C was diagnosed in 60 of 302 family members (18
symptomatic, 42 asymptomatic), of whom 54 (90%) carried
pathogenic mutations (all PKP2, 47 truncating). Identifying a
pathogenic mutation in an index patient predicts outcome in
relatives. Compared with relatives of index patients without
mutations, mutation-carrying relatives have a 6-fold risk of
ARVD/C diagnosis, markedly enhanced risk of ventricular
arrhythmias in analyzed relatives, and earlier onset of
ARVD/C signs and symptoms (for concurrent numbers, see
Familial Risk of Arrhythmogenic Right Ventricular Dyspla-
sia/Cardiomyopathy, Table 4, and Figure 4, respectively). In
young relatives 20 years of age, sudden death and signs of
ARVD/C occurred exclusively in PKP2 mutation carriers.
Prolonged TAD, a marker of activation delay, appeared to be
an early ARVD/C sign.
Pathogenicity of DNA Variants
The large majority of DNA variations were truncating PKP2
mutations. Notably, in this first study applying multiplex
ligation-dependent probe amplification on a large scale in
ARVD/C patients, large PKP2 deletions were identified in 3
cases. This mutational yield of 2%, which is comparable to
the sequencing of DSG2 or DSC2, underscores the impor-
tance of performing this additional analysis. Notably, because
this has not been tested, we cannot exclude the possibility that
large deletions might be present in other desmosomal genes
in patients that are as yet without a pathogenic mutation.
The fact that a significant proportion of genetic variants
remains unclassified represents a gap in risk assessment for
index patients, and UVs are noninformative for family
screening. However, establishing pathogenic effects of mis-
sense variants is difficult and requires well-validated func-
tional assays, which are not widely available and are highly
complex to perform. Linkage and segregational studies can be
helpful to establish pathogenicity. Yet, low frequency of
variants, small family size, and age-dependent penetrance
hamper the use of these methods.
Previous studies on mutations in DSC2, DSG2, and DSP
used different criteria to define the pathogenicity of DNA
variants. The largest studies used criteria of absence in
control subjects and/or occurrence in a functionally important
domain, alteration of conserved amino acids, or cosegrega-
Figure 4. Relatives showing any sign of
arrhythmogenic right ventricular dyspla-
sia/cardiomyopathy, ie, meeting 1 crite-
ria besides those concerning family his-
tory, divided into age groups. With
increasing age, higher percentages of rel-
atives showed signs of disease except in
at the highest age. Numbers between
parentheses indicate numbers of relatives
per age group, with and without mutation,
respectively.
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tion with disease in a family.21,22,30 Thus, in contrast to our
study, none of these studies used all the possible predictive
strategies together. Consequently, the variants p.Thr335Ala
and p.Val392Ile in DSG2 and p.Gln90Arg in DSP were
previously classified as pathogenic, but with our definition,
they were classified as UVs.21,22
Index Patients
In this study of white Dutch patients, PKP2 was by far the
most important contributor to mutation yield (found in 52%
of patients, 90% of pathogenic mutations). Previous studies
reported PKP2 mutations in 19% to 45% of ARVD/C patients
and mutations in other desmosomal genes in 1% to
12%.21,22,31,32 These differences can be due to various causes,
such as the presence of founder mutations, use of different
definitions for pathogenicity, regional differences in other
genetic and nongenetic causes, and strictness in applying the
TFC.6,19 New genetic techniques, such as high-density geno-
typing array with haplotype sharing or exome sequencing,
might elucidate new genes involved in ARVD/C.33 This will
improve the distinction between familial and sporadic
ARVD/C cases and ameliorate risk stratification for relatives.
Our study suggests that UVs as defined here do not
result in a more severe phenotype or earlier onset of
ARVD/C. However, most UVs were found only in single
patients; therefore, comparisons on the level of individual
variants were not possible. Because the pathogenic influ-
ence of UVs is unknown, relatives were not tested for these
variants. Consequently, it cannot be ruled out that, within
families, carrying a specific UV is a risk factor for disease
development.
Index patients were included only if they fulfilled the 2010
TFC. Consequently, this obviously affected population can-
not be regarded as representative of the variable disease
expression. Therefore, analysis of asymptomatic family
members was crucial.
Family Members
The large majority (84%) of initially asymptomatic family
members showing signs of ARVD/C carried desmosomal
gene mutations (90% truncating, all PKP2). Overall, we
found no differences between carriers of truncating and
missense mutations. In 4 families with 2 members diag-
nosed with ARVD/C and in whom no mutations were
identified, a genetic cause is highly suspected.
Negative T waves in V1 to V3 have always been considered
the most sensitive ECG abnormality in ARVD/C.17–20 How-
ever, in family members, we observed the new criterion of
prolonged TAD more often and at younger age (Figure 3). In
4 of 7 family members 20 years of age with signs of
ARVD/C, prolonged TAD was the only clinical abnormality
observed. Longer periods of follow-up are needed to demon-
strate the disease progression after prolonged TAD is found
and whether it is a good predictive marker of arrhythmias and
SCD.
Disease Penetrance
Because ARVD/C is a progressive disease with age-related
penetrance, it seems counterintuitive that the percentage of
family members showing any signs of ARVD/C was lower in
those 50 years of age than in their younger counterparts.
Because individuals 50 years of age are also at higher risk
of coronary artery disease, those already seeing a cardiologist
may not have been referred for family screening.
Cohorts of ARVD/C index patients universally demon-
strate a male predominance.18–21 Interestingly, among the
asymptomatic family members in this study, women were
affected more often than men. Apparently, men with
ARVD/C experience arrhythmias and die suddenly at a
younger age and thus are more likely to be the index patient.
The underlying mechanism is not yet known, but strenuous
exercise by men and the prevention of programmed cell death
in cardiac myocytes in women due to estradiol are believed to
play a role.34
At first examination, 43 of 282 asymptomatic family
members (15%) already showed any sign of disease, includ-
ing nonsustained VT in 5 patients and 500 premature
ventricular complexes in 24 hours in 30 patients. Because
relatives with these arrhythmias were asymptomatic, the age
of onset is unknown. Besides, only 4 relatives (all mutation
carriers) went on to develop VT during follow-up. Therefore,
it was not possible to calculate the annual risk of arrhythmias
or to identify predictive risk factors other than carrying a
pathogenic mutation. Longer periods of follow-up of large
series of relatives who initially have no signs of disease are
needed to provide this insight. Large multicenter studies are
required to achieve this.
Contrary to our study, all previous genotype-phenotype
analyses in ARVD/C families separately addressed mutations
in different desmosomal genes and involved only a few
families. We found that 66 of 137 mutation-carrying family
members (48%) showed some sign of ARVD/C, with
ARVD/C diagnosis made according to 2010 TFC in 39%. No
direct comparison with other studies can be made, because
different sets of diagnostic criteria were used. However,
similar numbers of affected relatives with PKP2 mutations
were reported by Dalal et al35 and Syrris et al20 (49% and
47%, respectively). Other family studies have also reported
high percentages of relatives diagnosed with ARVD/C: 58%
in DSG2, 75% in DSC2, and 54% in DSP mutation carriers.
However, these studies comprised only 8, 2, and 4 families,
respectively.8,30,36
Study Limitations
Sequence alterations were divided into pathogenic or UVs
according to arbitrarily defined criteria. However, in the
absence of any data on pathogenicity, conclusions regarding
the utility of genetic testing are speculative.
All index patients were offered family screening, regard-
less of their mutational status. However, relatives of 93 of
149 fully genotyped index patients (62%) underwent both
clinical and genetic screening. Although there is no such
indication, this might potentially create a bias in the popula-
tion of relatives studied. Not all relatives underwent all the
diagnostic tests, as indicated in the Methods section. All
family members included in this study underwent at least
2-dimensional echocardiography to screen for RV structural
abnormalities. Additional magnetic resonance imaging was
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performed in only a minority of cases, so minor abnormalities
might have been missed. Late potentials were measured in
25% of relatives, but activation delay was measured by means
of prolonged TAD in all relatives.
Thirty-six relatives of mutation-carrying index patients
were not clinically evaluated because they appeared to be
noncarriers; thus, they could not be included in this study.
Consequently, of families with pathogenic mutations, more
relatives with mutations were included than without muta-
tions (119 versus 67).
Conclusions
In this large follow-up study in Dutch ARVD/C families,
pathogenic desmosomal gene mutations were found in the
majority of ARVD/C index patients (58%); these were
mainly truncating PKP2 mutations, with multiple mutations
in 2% of cases. Performing multiplex ligation-dependent
probe amplification also is important, because its mutational
yield is comparable to the sequencing of DSG2 or DSC2.
Mutation carriers presented at a younger age than noncarriers;
this age was even lower when multiple mutations were
identified.
In total, 20% of initially asymptomatic relatives who
underwent family screening showed some sign of ARVD/C
(84% mutation carriers), mainly ECG abnormalities.
Mutation-carrying relatives had an earlier onset of signs and
symptoms, a markedly increased risk of arrhythmias, and a
6-fold increased risk of ARVD/C diagnosis. Familial cases
were identified in 45% of the families screened. Prolonged
TAD seems to be an early marker of RV abnormalities,
especially in mutation-carrying relatives 20 years of age.
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CLINICAL PERSPECTIVE
Arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C) usually shows an autosomal dominant inheritance
pattern, with incomplete penetrance and variable clinical expression. Classically, index patients present between the second
and fourth decades of life with right ventricular tachycardia. However, sudden death can occur at adolescence, whereas
mutation carriers may remain without signs and symptoms until old age. Previous genotype-phenotype studies involved
mainly overt index patients. Data on mainly asymptomatic relatives were scarce. To gain insight into the full spectrum of
the disease, 149 ARVD/C index patients and 302 of their relatives were genotypically and phenotypically characterized.
DNA analysis comprised sequencing of the desmosomal genes PKP2, DSC2, DSG2, DSP, and JUP and multiplex
ligation-dependent probe amplification to identify large deletions in PKP2. Pathogenic mutations were identified in 87 of
149 ARVD/C index patients (58%), mainly truncating PKP2 mutations with multiple mutations in 2% of cases. Performing
multiplex ligation-dependent probe amplification also appeared to be important; its 2% mutational yield was comparable
to the sequencing of DSG2 or DSC2. Identification of mutations in index patients had major consequences for the
concurrent relatives. Of the 57 of 282 initially asymptomatic relatives (20%) who showed any sign of ARVD/C, 84%
carried a mutation. These 48 mutation carriers had earlier onset of disease signs and symptoms than noncarriers but also
a markedly increased risk of arrhythmias and 6-fold risk of ARVD/C diagnosis. Familial cases were identified in 45% of
families screened. Prolonged terminal activation duration seemed to be an early marker of ARVD/C; it was observed more
often than negative T waves in V1 to V3, especially in mutation-carrying relatives 20 years of age.
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SUPPLEMENTAL MATERIAL 
 
 
Supplemental Table 1: 
Follow-up Frequencies of Index-patients and Relatives 
 Index-Patients 
(n=147) 
Relatives 
(n=302) 
 mean±SD median (range) mean±SD median (range) 
Intervals (years) between     
Visits 0.5±0.3 0.3 (0.2-1.2) 1.1±0.6 1 (0.3-5.0) 
Echocardiography 3.6±2.3 2.8 (1-9) 1.7±1.5 1 (1-12) 
Exercise Tests 3.1±2.0 2.5 (0.8-9) 2.6±2.1 2 (1-10) 
24h Holter  5.1±4.7 2.5 (0.8-16) 2.6±2.0 2 (1-10) 
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 Supplemental Table 2: Unclassified Variants 
 
  
 
PolyPhen 
(PSIC)* SIFT
†
 
Index-
patients 
n  
Unclassified Variants 
PKP2 c.76G>A p.Asp26Asn Missense + (1.593) 0.15 2  
 c.174G>T Glu58Asp Missense - (1.248) 0.42 1  
 c.759C>T p.= Silent   1  
 c.1378G>A p.Asp460Asn Missense - (0.0) 0.45 1  
DSC2 c.1807A>C p.Ile603Leu Missense - (1.157) 0.20 1  
 c.1914G>T p.Gln638His Missense + (1.710) 0.01
‡
 1  
 c.2194T>G p.Leu732Val Missense - (0.197) 0.15 2  
 c.2393G>A p.Arg798Gln Missense - (0.716) 0.00
‡
 1  
 c.2686_2687dupGA p.Ala897LysfsX4 Frameshift   8  
DSG2 c.445G>T p.Val149Phe Missense + (1.747) 0.00
‡
 1  
 c.473T>G p.Val158Gly Missense ++ (2.470) 0.00
‡
 2  
 c.783T>A p.= Silent   1  
 c.889G>A p.Asp297Asn Missense + (1.951) 0.00
‡
 1  
 c.1003A>G p.Thr335Ala Missense + (1.559) 0.00
‡
 3  
 c.1072G>A p.Ala358Thr Missense + (1.760) 0.00
‡
 1  
 c.1174G>A p.Val392Ile Missense - (0.813) 0.14 1  
 c.1303G>A p.Asp435Asn Missense - (1.459) 0.19 1  
 c.1480G>A p.Asp494Asn Missense + (1.790) 0.00
‡
 1  
 c.2137G>A p.Glu713Lys Missense + (1.632) 0.09 1  
 c.2194T>G p.Phe732Val Missense - (0.217) 0.56 1  
 c.2623A>G p.Met875Val Missense - (0.682) 0.65 1  
 c.2759T>G p.Val920Gly Missense + (1.936) 0.21 1  
DSP c.105G>A p.= Silent   1  
 c.269A>G p.Gln90Arg Missense - (1.432) 0.00
‡
 1  
 c.1696G>A p.Ala566Thr Missense - (1.227) 0.00
‡
 1  
 c.2346C>T p.= Silent   1  
 c.4372C>G p.Arg1458Gly Missense + (1.727) 0.03
‡
 1  
 c.4775A>G p.Lys1592Arg Missense - (1.047) 0.00
‡
 1  
 c.5218G>A p.Glu1740Lys Missense - (1.267) 0.00
‡
 2  
 c.5498A>T p.Glu1833Val Missense + (1.942) 0.00
‡
 1  
 c.6449C>G p.Ala2150Gly Missense - (0.986) 0.08 1  
JUP c.297G>A p.= Silent   1  
 c.1359G>T p.Glu453Asp Missense + (1.616) 0.00
‡
 1  
 c.1563A>G p.= Silent   2  
 c.1942G>A p.Val648Ile Missense - (0.417) 1.00 1  
        
* PolyPhen prediction: ++ probably damaging; + possibly damaging; - benign; † SIFT prediction: Amino acids with scores < 0.05 are 
predicted to be deleterious. For previous reports on pathogeneity: see reference 31; ‡This substitution may have been predicted to 
affect function just because the sequences used were not diverse enough.  There is low confidence in this prediction; § The 4 splice-
prediction programs used (SpliceSiteFinder, MaxEntScan, NNSPLICE and GeneSplicer) indicated disruption the splice donor site of 
DSC2 exon 7. 
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Supplemental Table 3: Clinical Characteristics of ARVD/C Probands with 2 Pathogenic Mutations 
Gender 
Mutation 
 1 
Mutation 
2 
Age First VT 
(years) 
Depolarization 
Abnormalities 
Repolarization 
Abnormalities: 
Arrhythmias 
 
Structural 
Abnormalities 
    ε LP TAD 
Negative T 
waves V1-3 LBBB VT  
v 
PKP2: 
917-918delCC 
DSC2: 
2587G>A 14    ++ + ++ 
          
v 
PKP2: 
2489+4A>C 
DSP: 
1982A>T 
20 ++  + ++ ++ ++ 
          
v 
DSC2: 
608G>A homozygous
 * 17 ++  + ++ + ++ 
ε = epsilon waves, LP= late potentials, TAD = prolonged terminal activation duration; LBBB VT: ventriculat tachycardia with left bundle branch block morphology 
+ minor criterion, ++ major criterion; * Parents were f irst degree cousins 
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 Supplemental Table 4: Combinations of Pathogenic Mutations and/or Unclassified Variants 
 PKP2 DSC2 DSG2 DSP JUP 
2 Mutations (+UV) 
 917-918delCC 2587G>A    
 2489+4A>C   1982A>T      
 
 
608G>A 
homozygous    
1 Mutation + UV 
 deletion exon 8    2686_2687dupGA   
 deletion exon 
1-14  1072G>A   
 148_151delAC
AG 2686_2687dupGA   
 235C>T 2686_2687dupGA   
 235C>T  1003A>G   
 235C>T  1174G>A   
 397C>T  1480G>A    
 397C>T  2623A>G    
 397C>T  2759T>G   
 917_918delCC  473T>G    
 1211-1212insT 2194T>G    
 1211-1212insT 2686_2687dupGA   
 1211-1212insT   269A>G 
 1211-1212insT   5218G>A  
 1848C>A    1942G>A 
 2146-1G>C  1696G>A   
 2386T>C   1003A>G    
 2386T>C    297G>A 
 2421C>A 2686_2687dupGA   
 2489+1G>A  1303G>A    
 2489+4A>C   5218G>A  
 2489+1G>A    1563A>G 
 2489+4A>C      
 2544G>A 2686_2687dupGA   
  943-1G>A  6449C>G 
   874C>T 2346C>T 
   137G>A + 473T>G              
   137G>A + 473T>G  
    3337C>T 4372C>G 
      
2 UVs  2194T>G 1174G>A   
   445G>T  1359G>T 
UV= unclassified variant; In bold: (most likely) pathogenic mutations; In italics: missense 
and silent variants. 
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 Supplemental Table 5: Clinical Characteristics of ARVD/C Index-Patients  
Related to Pathogenic Mutations and Unclassified Variants 
  Mutations and Unclassified Variants (UVs) 
  0 uv 1 1+uv 2 
n  40 20 55 29 3 
% male 81 76 78 66 0 
age onset (years±SD) 41±14 38±12 35±12 34±15 17±3 
 
     
 
n (%) n (%) n (%) n (%) n (%) 
epsilon wave 
†
 7 (24) 1 (6) 10 (19) 2 (7) 2 (67) 
late potentials 
‡
 14 (47) 8 (67) 11 (31) 11 (52) 0 
prolonged TAD
†
 24 (83) 10 (56) 30 (57) 12 (52) 2 (67) 
negative T waves V1-3 
†
 18 (62) 11 (61) 45 (85) 21 (72) 3 (100) 
negative T waves V1-2 
†
 1 (3) 2 (11) 4 (8) 1 (3) 0 
negative T waves V4-6 
†
 1 (3) 2 (11) 1 (2) 1 (3) 0 
LBBB VT superior axis 17 (43) 11 (55) 24 (44) 14 (48) 1 (33) 
LBBB VT  34 (85) 18 (90) 48 (87) 26 (90) 3 (100) 
PVCs >500 per 24h 9 (23) 4 (20) 14 (25) 5 (17) 1 (33) 
structural major TFC 17 (43) 14 (70) 32 (58) 20 (69) 3 (100) 
structural minor TFC 8 (20) 2 (10) 12 (22) 3 (10) 0 
†    Of 125 probands, ECGs while off drugs were available; ‡  In 81 patients late potentials were measured: 69 by 
SAECG, 12 by mapping during EPS; TAD: terminal activation duration, LBBB VT: ventricular tachycardia with left bundle 
branch block morphology, PVCs: premature ventricular complexes, TFC: Task Force Criteria. 
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